Apixaban Dosing and Antithrombotic Strategy When Combined With Dual Antiplatelet Therapy

1. Apixaban Dosing Principles

• Use the standard apixaban dose (5 mg twice daily) unless a patient meets ≥2 of the three dose‑reduction criteria (age ≥ 80 years, weight ≤ 60 kg, serum creatinine ≥ 1.5 mg/dL), in which case a reduced dose of 2.5 mg twice daily is appropriate. The dose should be determined solely by these criteria, not by concurrent antiplatelet therapy. 2

• Do not lower the apixaban dose simply because the patient is receiving dual antiplatelet therapy (DAPT). Continue the standard or criteria‑based reduced dose and discontinue aspirin as soon as safely possible, maintaining only the P2Y12 inhibitor with the anticoagulant. (Level A evidence from randomized trials). [1][2]

2. Duration of Antithrombotic Regimens

• Triple therapy (anticoagulant + aspirin + P2Y12 inhibitor):

  • For acute coronary syndrome (ACS) patients, limit triple therapy to a maximum of 1–7 days after the index event, then switch to dual therapy. [1][2]
  • For stable ischemic heart disease or elective percutaneous coronary intervention (PCI), limit aspirin exposure to ≤ 72 hours post‑procedure. 1
  • When aspirin is used, the dose should not exceed 100 mg daily. 1

• Dual therapy (anticoagulant + P2Y12 inhibitor only):

  • Continue apixaban at the standard or criteria‑based reduced dose together with clopidogrel 75 mg daily (preferred over prasugrel or ticagrelor). [1][2]
  • Duration of dual therapy: 12 months for ACS patients and 6 months for stable ischemic heart disease patients. 2

3. Preferred P2Y12 Inhibitor

• Clopidogrel is the recommended P2Y12 inhibitor when combined with apixaban; prasugrel and ticagrelor should be avoided in this context. (Level A evidence). 1

4. Special Populations & High Bleeding‑Risk Considerations

• Patients at very high bleeding risk may have the P2Y12 inhibitor discontinued earlier: after 3 months in stable ischemic heart disease and after 6 months in ACS. (Individualized decision‑making required). 2

• When shortening P2Y12 inhibitor therapy, clinicians must balance the reduced bleeding risk against the potential for stent thrombosis, especially in patients with complex lesions, prior myocardial infarction, or extensive atherosclerotic disease. 2

5. Key Recommendations (Avoid Common Pitfalls)

• Do not reduce apixaban dose based on antiplatelet use; adhere strictly to the established dose‑reduction criteria. 2
• Do not extend aspirin beyond the initial post‑ACS/PCI period (beyond 30 days) because the incremental bleeding risk outweighs any additional ischemic benefit. 1
• Avoid triple therapy longer than 1 week for ACS or 3 days for elective PCI to prevent unnecessary bleeding without improving ischemic outcomes. 1

All statements are derived from the American College of Cardiology (ACC) guidance and supported by the cited references.